-
公开(公告)号：US20050014168A1
公开(公告)日：2005-01-20
申请号：US10769476
申请日：2004-01-30
申请人： Mark Erlander , Xiao-Jun Ma , Thomas Baer
发明人： Mark Erlander , Xiao-Jun Ma , Thomas Baer
CPC分类号： C12Q1/6876 , C12Q1/6809 , C12Q1/6851 , C12Q1/686 , C12Q2565/501
摘要： The invention provides materials and methods for the detection of nucleic acid expression via the 3′ portion of expressed sequences. Embodiments of the invention include the use of microarrays comprising nucleic acid probes that are complementary to the 3′ end of expressed sequences and by the use of quantitative PCR (Q-PCR) based amplification of sequences found at or near the 3′ end of expressed sequences. The invention may be used to detect the presence of expressed nucleic acids encoding particular gene products (sequences present in a “transcriptome”).
摘要翻译： 本发明提供了通过表达序列的3'部分检测核酸表达的材料和方法。 本发明的实施方案包括使用包含与表达的序列的3'末端互补的核酸探针的微阵列，以及通过使用基于定量PCR（Q-PCR）的扩增在3'末端发现的序列的表达 序列。 本发明可用于检测编码特定基因产物（“转录组”中存在的序列）的表达的核酸的存在。
-
公开(公告)号：US20060154267A1
公开(公告)日：2006-07-13
申请号：US11089097
申请日：2005-03-24
申请人： Xiao-Jun Ma , Mark Erlander , Dennis Sgroi , Edward Enright
发明人： Xiao-Jun Ma , Mark Erlander , Dennis Sgroi , Edward Enright
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/154 , C12Q2600/158 , G06Q50/22
摘要： Methods and compositions are provided for the identification of expression signatures in ER+ breast cancer cases, where the signatures correlate with responsiveness, or lack thereof, to treatment with tamoxifen or another antiestrogen agent against breast cancer The signature profiles are identified based upon sampling of reference breast tissue samples from independent cases of breast cancer and provide a reliable set of molecular criteria for predicting the efficacy of treating a subject with breast cancer with tamoxifen or another antiestrogen agent against breast cancer. Additional methods and compositions are provided for predicting responsiveness to tamoxifen or another antiestrogen agent against breast cancer in cases of breast cancer by use of multiple biomarkers. Two biomarkers display increased expression correlated with tamoxifen response while two other biomarkers display decreased expression correlated with tamoxifen response.
摘要翻译： 提供了方法和组合物用于鉴定ER +乳腺癌病例中的表达标志，其中签名与反应性或缺乏相关，与他莫昔芬或另一种针对乳腺癌的抗雌激素剂的治疗相关。基于参考乳腺的抽样来鉴定签名谱 来自乳腺癌独立病例的组织样本，并提供可靠的一组分子标准，用于预测使用他莫昔芬或其他抗雌激素剂对乳腺癌进行乳腺癌治疗的受试者的疗效。 提供了另外的方法和组合物，用于通过使用多种生物标志物来预测在乳腺癌病例中对他莫昔芬或另一种抗雌激素剂对乳腺癌的反应性。 两种生物标志物显示与他莫昔芬反应相关的增加的表达，而另外两种生物标志物显示与他莫昔芬反应相关的降低的表达。
-
公开(公告)号：US20050239083A1
公开(公告)日：2005-10-27
申请号：US10773761
申请日：2004-02-06
申请人： Mark Erlander , Xiao-Jun Ma , Dennis Sgroi
发明人： Mark Erlander , Xiao-Jun Ma , Dennis Sgroi
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/154 , C12Q2600/158
摘要： Methods and compositions are provided for the identification of expression signatures in ER+ breast cancer cases, where the signatures correlate with responsiveness, or lack thereof, to treatment with tamoxifen or another antiestrogen agent against breast cancer The signature profiles are identified based upon sampling of reference breast tissue samples from independent cases of breast cancer and provide a reliable set of molecular criteria for predicting the efficacy of treating a subject with breast cancer with tamoxifen or another antiestrogen agent against breast cancer. Additional methods and compositions are provided for predicting responsiveness to tamoxifen or another antiestrogen agent against breast cancer in cases of breast cancer by use of three biomarkers. Two biomarkers display increased expression correlated with tamoxifen response while the third biomarker displays decreased expression correlated with tamoxifen response.
摘要翻译： 提供了方法和组合物用于鉴定ER +乳腺癌病例中的表达标志，其中签名与反应性或缺乏相关，与他莫昔芬或另一种针对乳腺癌的抗雌激素剂的治疗相关。基于参考乳腺的抽样来鉴定签名谱 来自乳腺癌独立病例的组织样本，并提供可靠的一组分子标准，用于预测使用他莫昔芬或其他抗雌激素剂对乳腺癌进行乳腺癌治疗的受试者的疗效。 提供了另外的方法和组合物，用于通过使用三种生物标志物来预测在乳腺癌病例中对他莫昔芬或另一种针对乳腺癌的抗雌激素剂的反应性。 两种生物标志物显示与他莫昔芬反应相关的增加的表达，而第三种生物标志物显示与他莫昔芬反应相关的降低的表达。
-
公开(公告)号：US20050255481A1
公开(公告)日：2005-11-17
申请号：US10843717
申请日：2004-05-11
申请人： Xiao-Jun Ma , Edward Enright , Mark Erlander
发明人： Xiao-Jun Ma , Edward Enright , Mark Erlander
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/112 , C12Q2600/156
摘要： The invention relates to the identification and use of sequences from expressed progesterone receptor transcripts in relation to breast cancer. In particular, the invention provides the identities of polynucleotide sequences that may be used to identify populations that are positive for estrogen receptor expression. The expressed polynucleotide sequences may be used in the study and/or diagnosis of cells and tissue in breast cancer as well as for the study and/or determination of prognosis of a patient.
摘要翻译： 本发明涉及鉴定和使用与乳腺癌相关的来自表达的孕酮受体转录物的序列。 特别地，本发明提供可用于鉴定对雌激素受体表达呈阳性的群体的多核苷酸序列的身份。 表达的多核苷酸序列可用于研究和/或诊断乳腺癌中的细胞和组织，以及用于研究和/或确定患者的预后。
-
公开(公告)号：US20120258442A1
公开(公告)日：2012-10-11
申请号：US13083552
申请日：2011-04-09
申请人： Mark Erlander , Xiao-Jun Ma
发明人： Mark Erlander , Xiao-Jun Ma
CPC分类号： C12Q1/6888 , C12Q1/6886 , C12Q2600/112 , C12Q2600/158 , C12Q2600/16
摘要： The disclosure provides methods for the use of gene expression measurements to classify or identify among 54 cancer types in samples obtained from a subject in a clinical setting, such as in cases of formalin fixed, paraffin embedded (FFPE) samples.
摘要翻译： 本公开提供了使用基因表达测量法在例如在福尔马林固定，石蜡包埋（FFPE）样品的情况下从临床环境中从受试者获得的样品中的54种癌症类型中进行分类或鉴定的方法。
-
公开(公告)号：US20050100933A1
公开(公告)日：2005-05-12
申请号：US10871869
申请日：2004-06-18
申请人： Mark Erlander , Xiao-Jun Ma , Wei Wang , James Wittliff
发明人： Mark Erlander , Xiao-Jun Ma , Wei Wang , James Wittliff
IPC分类号： C12P19/34 , C12Q1/68 , G01N33/574
CPC分类号： G01N33/57415 , C12Q1/6886 , C12Q2600/106 , C12Q2600/112 , C12Q2600/118 , C12Q2600/158
摘要： The invention provides for the identification and use of gene expression profiles, or patterns, with clinical relevance to breast cancer. In particular, the invention provides the identities of genes that are correlated with patient survival and breast cancer recurrence. The gene expression profiles may be embodied in nucleic acid expression, protein expression, or other expression formats and used to predict the survival of subjects afflicted with breast cancer and to predict breast cancer recurrence and. The profiles may also be used in the study and/or diagnosis of breast cancer cells and tissue, including the grading of invasive breast cancer, as well as for the study and/or determination of prognosis of a patient. When used for diagnosis or prognosis, the profiles may be used to determine the treatment of breast cancer based upon the likelihood of life expectancy and recurrence.
摘要翻译： 本发明提供了与乳腺癌临床相关的基因表达谱或模式的鉴定和使用。 特别地，本发明提供了与患者存活和乳腺癌复发相关的基因的身份。 基因表达谱可以体现在核酸表达，蛋白质表达或其他表达形式中，并用于预测患有乳腺癌的受试者的存活并预测乳腺癌复发。 轮廓也可以用于乳腺癌细胞和组织的研究和/或诊断，包括浸润性乳腺癌的分级，以及用于研究和/或确定患者的预后。 当用于诊断或预后时，可根据预期寿命和复发的可能性来确定乳腺癌的治疗方法。
-
公开(公告)号：US20070020655A1
公开(公告)日：2007-01-25
申请号：US11422056
申请日：2006-06-02
申请人： Mark Erlander , Xiao-Jun Ma
发明人： Mark Erlander , Xiao-Jun Ma
CPC分类号： G16B40/00 , C12Q1/6886 , C12Q2600/112 , G16B25/00
摘要： The invention provides methods for the use of gene expression measurements to classify or identify tumors in samples obtained from a subject in a clinical setting, such as in cases of formalin fixed, paraffin embedded (FFPE) samples.
摘要翻译： 本发明提供了使用基因表达测量法在临床环境中从受试者获得的样品中分类或鉴定肿瘤的方法，例如在福尔马林固定的石蜡包埋（FFPE）样品的情况下。
-
公开(公告)号：US20060263806A1
公开(公告)日：2006-11-23
申请号：US11381353
申请日：2006-05-02
申请人： Xiao-Jun Ma , Dennis Sgroi , Mark Erlander
发明人： Xiao-Jun Ma , Dennis Sgroi , Mark Erlander
CPC分类号： G01N33/57496 , C12Q1/6886 , C12Q2600/112 , C12Q2600/154 , C12Q2600/158 , G01N33/57415
摘要： Methods and compositions are provided for the detection of breast cancer based upon the identification of three biomarkers for non-normal breast cells. The biomarkers were identified based upon multiple sampling of reference breast tissue samples from independent cases of breast cancer. Two biomarkers display increased expression in non-normal cells while the third biomarker displays decreased expression in non-normal cells.
摘要翻译： 基于鉴定非正常乳腺细胞的三种生物标志物，提供了用于检测乳腺癌的方法和组合物。 基于来自独立乳腺癌病例的参考乳腺组织样品的多次取样来鉴定生物标志物。 两个生物标志物在非正常细胞中显示出增加的表达，而第三个生物标志物在非正常细胞中显示出降低的表达。
-
公开(公告)号：US20060088851A1
公开(公告)日：2006-04-27
申请号：US11145061
申请日：2005-06-03
申请人： Mark Erlander , Dennis Sgroi , Xiao-Jun Ma
发明人： Mark Erlander , Dennis Sgroi , Xiao-Jun Ma
IPC分类号： C12Q1/68 , G01N33/574
CPC分类号： C12Q1/6827 , C12Q1/6886 , C12Q2600/106 , C12Q2600/112 , C12Q2600/118 , C12Q2600/154
摘要： This invention relates to the detection of increased expression from the HoxB13 (homeobox B13) gene as indicative of an invasive or metastatic cancer phenotype. The invention provides methods of detecting the level of expression from the HoxB13 gene, optionally in combination with nodal status, as an indicator of the invasive or metastatic phenotype as well as increased cellular migration and/or mobility. The invention also provides for the measurement of expression from the HoxB13 gene to assist in the determination of patient prognosis as well as clinical diagnosis and treatment.
摘要翻译： 本发明涉及从HoxB13（同源盒B13）基因增加的表达的检测，指示侵袭性或转移性癌症表型。 本发明提供了检测来自HoxB13基因的表达水平的方法，任选地与结节状态组合，作为侵袭性或转移表型的指标以及增加的细胞迁移和/或迁移率。 本发明还提供了来自HoxB13基因的表达的测量以帮助确定患者的预后以及临床诊断和治疗。
-
公开(公告)号：US20050239079A1
公开(公告)日：2005-10-27
申请号：US10727100
申请日：2003-12-02
申请人： Mark Erlander , Xiao-Jun Ma , Dennis Sgroi
发明人： Mark Erlander , Xiao-Jun Ma , Dennis Sgroi
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/112 , C12Q2600/154 , C12Q2600/158
摘要： Methods and compositions are provided for the identification of expression signatures in ER+ breast cancer cases, where the signatures correlate with responsiveness, or lack thereof, to tamoxifen treatment. The signature profiles are identified based upon sampling of reference breast tissue samples from independent cases of breast cancer and provide a reliable set of molecular criteria for predicting the efficacy of treating a subject with ER+ breast cancer with tamoxifen. Additional methods and compositions are provided for predicting tamoxifen responsiveness in cases of ER+ breast cancer by use of three biomarkers. Two biomarkers display increased expression correlated with tamoxifen response while the third biomarker displays decreased expression correlated with tamoxifen response.
摘要翻译： 提供方法和组合物用于鉴定ER +乳腺癌病例中的表达标志，其中签名与他莫昔芬治疗的反应性或缺乏相关。 基于来自乳腺癌独立病例的参考乳腺组织样本的抽样来鉴定特征谱，并提供可靠的一组分子标准，用于预测使用他莫昔芬治疗患有ER +乳腺癌的受试者的功效。 提供了另外的方法和组合物，用于通过使用三种生物标志物来预测ER +乳腺癌患者中的他莫昔芬反应性。 两种生物标志物显示与他莫昔芬反应相关的增加的表达，而第三种生物标志物显示与他莫昔芬反应相关的降低的表达。
-
-
-
-
-
-
-
-
-
搜索结果
36 条记录 (耗时 0.036 秒)
